Anavex Life Sciences Corp. (FRA:12X1)

Anavex Life Sciences Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Cash & Equivalents	102.58	132.19	151.02	149.16	152.11
Cash & Short-Term Investments	102.58	132.19	151.02	149.16	152.11
Cash Growth	-22.40%	-12.47%	1.25%	-1.94%	420.04%
Other Receivables	0.81	2.45	2.71	3.19	9.14
Receivables	0.81	2.45	2.71	3.19	9.14
Prepaid Expenses	0.43	0.93	0.65	0.35	0.37
Total Current Assets	103.82	135.57	154.39	152.71	161.62
Total Assets	103.82	135.57	154.39	152.71	161.62
Accounts Payable	4.25	9.63	4.32	3.83	4.74
Accrued Expenses	3.89	4.84	7.3	5.95	5.61
Current Unearned Revenue	0.81	0.84	0.92	0.44	0.44
Total Current Liabilities	8.95	15.3	12.53	10.21	10.8
Total Liabilities	8.95	15.3	12.53	10.21	10.8
Common Stock	0.09	0.09	0.08	0.08	0.08
Additional Paid-In Capital	477.23	456.25	434.84	387.98	348.33
Retained Earnings	-382.45	-336.07	-293.07	-245.56	-197.59
Shareholders' Equity	94.87	120.26	141.85	142.49	150.82
Total Liabilities & Equity	103.82	135.57	154.39	152.71	161.62
Net Cash (Debt)	102.58	132.19	151.02	149.16	152.11
Net Cash Growth	-22.40%	-12.47%	1.25%	-1.94%	420.04%
Net Cash Per Share	1.20	1.58	1.89	1.94	2.18
Filing Date Shares Outstanding	89.35	84.82	82.09	77.96	76.02
Total Common Shares Outstanding	86.67	84.8	82.07	77.94	75.92
Working Capital	94.87	120.26	141.85	142.49	150.82
Book Value Per Share	1.09	1.42	1.73	1.83	1.99
Tangible Book Value	94.87	120.26	141.85	142.49	150.82
Tangible Book Value Per Share	1.09	1.42	1.73	1.83	1.99

Source: S&P Global Market Intelligence. Standard template. Financial Sources.